November 8, 2022 01:20 PM ESTUpdated November 11, 03:04 PM
Bioregnum
R&D

Am­gen may be way late to the obe­si­ty game, but the mar­ket scouts are lov­ing the block­buster po­ten­tial of AMG 133

Am­gen has been dan­gling an­oth­er snap­shot of ear­ly-stage da­ta from its obe­si­ty drug AMG 133. And the an­a­lysts have been grab­bing it and beg­ging for …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times